PDCD1 and esophageal squamous cell carcinoma: To date, the only clear benefit of adding anti-PD-1/PD-L1 ICIs to standard-of-care treatments has been observed with the use of adjuvant nivolumab in patients with locally advanced ESCC who have received neoadjuvant CRT [39].